Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. inge is advising Xspray Pharma in connection with its rights issue
Mandate

Vinge is advising Xspray Pharma in connection with its rights issue

December 03, 2024 Capital Markets and Public M&A

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Joel Magnusson, Adrian Filipovic and Elias Kröger.

Related

Vinge has advised Consolid on the establishment of Consolid Equity III

 The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025

Vinge advises EQT VIII in connection with the divestment of Recover to Pangea AS

 Recover is a leading Scandinavian property remediation specialist. Following EQT’s acquisition in 2020, Recover has invested in its digital capabilities while divesting non-core business units to sharpen focus on water, fire and other core property remediation services.
July 02, 2025

Vinge advises XPartners on its issuance of senior secured bonds

 Vinge advises XPartners Samhällsbyggnad AB (“XPartners”) in connection with its SEK 3 billion issuance of senior secured bonds
July 02, 2025